Summary:
India has formed an expert committee comprising representatives from all relevant ministries and institutions to oversee all aspects of its Covid-19 vaccine plan, from identification of the vaccine to buying to financing the purchase to distribution and administration — a move that comes even as six vaccines are in Phase 3 or combined Phase 2-3 trials and as countries around the world scramble to strike deals with multiple vaccine makers.
.
New Delhi: India has formed an expert committee comprising representatives from all relevant ministries and institutions to oversee all aspects of its Covid-19 vaccine plan, from identification of the vaccine to buying to financing the purchase to distribution and administration — a move that comes even as six vaccines are in Phase 3 or combined Phase 2-3 trials and as countries around the world scramble to strike deals with multiple vaccine makers.
According to people familiar with the matter who asked not to be named, the panel will be led by Niti Aayog’s Dr VK Paul and co-chaired by health secretary Rajesh Bhushan.
It will pick the vaccine or vaccines that India can use, plan the finances for what is sure to be an expensive purchase running into billions of dollars, and prioritise the sequence of administration.
In the absence of a vaccine or a cure, the only way to slow the spread of Covid-19 has been wearing masks, social distancing, and restricting regular activities — things that have taken a toll on life and work.
Till Friday night, the coronavirus disease had infected 19,385, 292 people around the world and killed 720, 053.
In India, the corresponding numbers are 2,083, 835 and 42,566.
HT was the first to report on July 27 that Indian officials were already discussing a wide range of issues related to the vaccine, from logistics to prioritisation, to setting the stage for a smooth supply and effective use of the vaccine.
The high-level panel, formed by the cabinet secretary on Friday, includes AIIMS director Dr Randeep Guleria, representatives of the ministries of external affairs, biotechnology, information technology, the Director General of Health services, India’s Aids Research Institute, the Indian Council of Medical Research, and also representatives from states.